Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on ROCHE HOLDING LTD.
01:20p ROCHE : Rituxan For Pemphigus Vulgaris Gets Breakthrough Therapy Designation
09:18a Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 ROCHE : FDA grants breakthrough therapy designation for MabThera/Rituxan (rituxi..
03/24 ROCHE : FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in ..
03/24 ROCHE : Rep. Speier to Host 'When I Grow Up...' for Elementary and Middle School..
03/22 ROCHE : Global Calcitriol (CAS 32222-06-3) Market- Roche, Sun Pharmaceutical Ind..
03/22 ROCHE : Westminster slips by Vulcans, 5-4
03/22 ROCHE : Oxford Preparatory Academy Sues Its Founder for Allegedly Diverting Fund..
03/21 ROCHE : Discuss the Freeze Drying of High Concentration Biologics in the Run-up ..
03/21 LOXO ONCOLOGY : LOXO) Enters Collaboration Agreement with Ventana Medical System..
03/21 LOXO ONCOLOGY : Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collabo..
03/20 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – SVP Sold 6,231 shares of Sto..
03/20 ROCHE : Health and Human Services Department (HHS); Food and Drug Administration..
03/20 ROCHE : Does Mars Have Rings? Not Right Now, But Maybe One Day
03/18 ROCHE : Soap veteran Ken 'no diva'
03/17 ROCHE : New MagNA Pure 24 System by Roche offers labs improved flexibility and a..
03/17 YESTAR HEALTHCARE : Health to add remaining stake in Biotech
03/16 ROCHE HOLDING LTD. : ex-dividend day for annual dividend
03/15 SBI Pharma and Chugai Enter an Agreement ofExclusive Marketing Rights for 'AL..
03/15 ROCHE : Diagnostics recognizes Poplar Healthcare as Roche Molecular Center of Ex..
03/14 ROCHE : launches the cobas® EGFR Mutation Test v2 for use with either plasma or ..
03/14 ROCHE : Annual General Meeting 2017
03/14 ROCHE : Mylans pathway to launch of biosimilar to Herceptin cleared by Roche
03/11 ROCHE : U.S. Patents Awarded to Inventors in New Hampshire (March 11)
03/11 ROCHE : U.S. Patents Awarded to Inventors in Massachusetts (March 11)
03/11 ROCHE : Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq ..
03/10 ROCHE : Supply and maintenance of software for accounting
03/10 ROCHE : Results for Prothenas Phase 1b Multiple Ascending Dose Study of PRX002/R..
03/10 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – Director Sold 40,000 shares ..
03/10 Global Cytokines Market 2017- AbbVie, Roche, Pfizer, Sanofi, Johnson & Johnso..
03/09 Genentech & Bristol-Myers Squibb Dominate Franchise Image, Overall Engagement..
03/09 FOUNDATION MEDICINE : Receives Medicare Payment in Non-Small Cell Lung Cancer un..
03/09 EXELIXIS : Announces Clinical Trial Collaboration with Roche to Evaluate Cabozan..
03/09 FOUNDATION MEDICINE : to Present at Cowen and Company's 37th Annual Healthcare C..
03/09 CHUGAI PHARMACEUTICAL : Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nem..
03/09 Development costs to keep Merck KGaA profit flat this year
03/09 Germany's Merck well advanced in talks to sell biosimilars unit
03/08 ROCHE : $221,611 Federal Contract Awarded to Roche Diagnostics
03/07 European shares slip as Trump tweet hits drugmakers
03/06 GLOBAL MOLECULAR DIAGNOSTICS INDUSTR : Roche, Qiagen, Danaher, GE
03/06 ROCHE : Statement
03/04 SETBACK FOR ROCHE : Mylan, Biocon can now sell generics of its cancer drug
03/04 BIOCON, MYLAN BREAST CANCER DRUGS AP : HC told
03/04 BIOCON : Mylan allowed to sell 3 cancer biosimilars
03/03 CHUGAI PHARMACEUTICAL : Anti-IL-31 Receptor A Humanized Monoclonal Antibody 'nem..
03/03 ROCHE : Phase III APHINITY Study Shows Genentech's Perjeta Regimen Helped People..
03/02 FOUNDATION MEDICINE, INC. (NAS : FMI) Files An 8-K Other Events
03/02 FOUNDATION MEDICINE, INC. : Other Events, Financial Statements and Exhibits (for..
03/02 ROCHE : Phase III APHINITY study shows Roche's Perjeta® regimen helped people wi..
03/02DJROCHE : Posts Positive Results From Breast-Cancer Drug Trial
03/02 ROCHE : Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped..
03/01 ROCHE : Supply of chemicals
03/01 ROCHE : receives EU approval of Alecensa (alectinib) for people with previously ..
03/01 ROCHE : (3) Haddon Township 59, (14) Buena Regional 20
02/26 ROCHE : Behrend falls to La Roche in AMCC men's semifinals
02/26 ROCHE : PSAC men
02/25 ROCHE : Behrend men fall to La Roche in AMCC semifinals Staff reports
02/24 ROCHE : Presolicitation Notice - 1 year service & support contract for two Roche..
02/23 ROCHE : European Commission conditionally approves Roches cancer drug Alecensa
02/23 ROCHE : You 'cannot hang on to' breast cancer drug, high court tells roche
02/22 FOUNDATION MEDICINE : reports 4Q loss
02/22 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
02/22 ROCHE : TAC Calls for Roche to Drop Price of Cancer Drug
02/22 CHUGAI PHARMACEUTICAL : ALK Inhibitor 'Alecensa' Approved in the EUAlecensa is A..
02/22 ROCHE : Registration closing soon for 11th annual Paediatric Clinical Trials sho..
02/21 ROCHE : Enters Hematology Market with Integrated Analyzer
02/21 ROCHE : receives EU approval of Alecensa (alectinib) for people with previously ..
02/20 ROCHE : Global Histology Equipment Market- Leica, Roche, Sakura Finetek, Thermo ..
02/20 CHUGAI PHARMACEUTICAL : New Drug Application Filed for Immune Checkpoint Inhibit..
02/20 ROCHE : Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) p..
02/19 ROCHE : College basketball
02/18 ROCHE : Phase II study supports potential for Roche’s TECENTRIQ (atezolizu..
02/18 ROCHE : Phase II Study Supports Potential for Genentech’s Tecentriq® (Atez..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJROCHE : FBI Searches for Possible Accomplices in Probe of Fallen K Street Lobbyi..
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( CHF)
Sales 2017 53 182 M
EBIT 2017 18 423 M
Net income 2017 11 628 M
Debt 2017 8 702 M
Yield 2017 3,38%
P/E ratio 2017 18,54
P/E ratio 2018 16,87
EV / Sales 2017 4,26x
EV / Sales 2018 3,93x
Capitalization 217 738 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 281  CHF
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.219 545
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results